je.st
news
Tag: merck
Merck wins approval to use drug called Keytruda to treat some forms of lung cancer
2015-10-03 01:23:17| Biotech - Topix.net
Merck & Co. won approval in the U.S. to expand the use of its drug Keytruda to treat a form of advanced lung cancer, though only in patients whose tumors have a biological marker signaling the medicine may work.
Tags: called
forms
drug
approval
Merck and DNAtrix Announce Phase 2 Immuno-Oncology Collaboration in Patients with Aggressive Form of Brain Cancer
2015-10-01 14:00:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. & HOUSTON KENILWORTH, N.J. & HOUSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and DNAtrix today announced they have entered into an oncology clinical study collaboration to evaluate the efficacy and safety of DNX-2401, DNAtrixs oncolytic immunotherapy, in combination with KEYTRUDA (pembrolizumab), Mercks anti-PD-1 therapy, in a Phase 2, multi-centered study of patients with recurrent glioblastoma, the most aggressive form of brain cancer for which there is no cure. Language: English Contact: MerckMedia Relations:Pamela Eisele, 267-305-3558orAn Phan, 908-255-6325Investor Relations:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879orDNAtrixInvestor/Media Relations:Imran Alibhai, Ph.D.ialibhai@dnatrix.com Ticker Slug: Ticker: MRK Exchange: NYSE read more
Sigma-Aldrich and Merck KGaA, Darmstadt, Germany, Making Progress Toward Completion of Planned Acquisition
2015-09-30 12:31:09| Industrial Newsroom - All News for Today
ST. LOUIS Sigma-Aldrich Corporation (NASDAQ: SIAL) announced today it is making progress toward closing the planned acquisition of the Company by Merck KGaA, Darmstadt, Germany. The closing is now expected within the next two months. On August 11, 2015, Sigma-Aldrich and Merck announced they had obtained all...
Tags: making
germany
progress
planned
Merck KGaA, Darmstadt, Germany, And Pfizer Announce FDA Orphan Drug Designation For Investigational Immunotherapy Avelumab In Merkel Cell Carcinoma
2015-09-30 08:25:02| drugdiscoveryonline News Articles
Merck KGaA, Darmstadt, Germany, and Pfizer recently announced that the US Food and Drug Administration (FDA) has granted orphan drug designation for the investigational cancer immunotherapy avelumab* for the treatment of Merkel cell carcinoma (MCC), a rare and aggressive type of skin cancer
Tags: germany
cell
drug
announce
SYNDAX AND MERCK ANNOUNCE FIRST PATIENTS DOSED IN PHASE 1b/2 CLINICAL TRIAL OF ENTINOSTAT AND KEYTRUDA
2015-09-28 14:00:56| Merck.com - Product News
Dateline City: WALTHAM, Mass. and KENILWORTH, N.J. Clinical trial to assess safety and efficacy of immuno-oncology combination in patients with advanced NSCLC or melanoma WALTHAM, Mass. and KENILWORTH, N.J. Syndax Pharmaceuticals, Inc. and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the dosing of the first patients in the Phase 1b/2 clinical trial of Syndaxs entinostat in combination with Mercks anti-PD-1 therapy KEYTRUDA (pembrolizumab) in patients with non-small cell lung cancer (NSCLC) or melanoma. Language: English read more
Sites : [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] next »